EU/3/05/263:

Dimethyl sulfoxide

Table of contents

Overview

On 3 March 2005, orphan designation (EU/3/05/263) was granted by the European Commission to AOP Orphan Pharmaceuticals AG, Austria, for dimethyl sulfoxide for the treatment of severe closed traumatic brain injury.

Key facts

Active substance
Dimethyl sulfoxide
Intented use
Treatment of severe closed traumatic brain injury
Orphan designation status
Positive
EU designation number
EU/3/05/263
Date of designation
03/03/2005
Sponsor
AOP Orphan Pharmaceuticals AG
Wilheminenstrasse 91/II/f/5
1160 Wien, Austria
Telephone: +43 1 50 33 72 44
Telefax: +43 1 50 37 24 45
E-mail: office@aoporphan.at

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating
Average
1 rating